In the Claims:

This listing of claims replaces all prior versions and listing of claims in the application:

Listing of Claims:

1 to 53 (Cancelled).

54. (New) A method for enhancing the condition of unbroken skin of a mammal by reducing one or more of wrinkling, roughness, dryness, or laxity of the skin without increasing proliferation of dermal cells in the skin, the method comprising topically applying to the skin a composition comprising adenosine or an adenosine analog in an amount effective to enhance the condition of the skin without increasing dermal cell proliferation.

55. (New) The method of claim 54, wherein the composition comprises an adenosine analog in a concentration of about 10^{-4} M to 10^{-7} M.

56. (New) The method of claim 55, wherein the adenosine analog concentration is about 10^{-4} M.

57. (New) The method of claim 54, wherein the composition comprises adenosine in a concentration of about 10^{-4} M to 10^{-7} M.

58. (New) The method of claim 57, wherein the adenosine concentration is about 10^{-4} M.

59. (New) The method of claim 54, wherein the composition further comprises a conditioning agent.

60. (New) The method of claim 59, wherein the conditioning agent is a humectant, an emollient, or an occlusive agent.

61. (New) The method of claim 54, wherein the mammal is a human.

62. (New) The method of claim 54, wherein the skin comprises a skin graft.

63. (New) The method of claim 54, wherein the composition further comprises a transdermal delivery agent.

64. (New) The method of claim 54, wherein the composition is in a transdermal patch and the composition is topically applied by contacting the patch to the skin.

65. (New) The method of claim 54, wherein the adenosine analog is selected from the group consisting of 2'-deoxyadenosine; 2',3'-isopropoylidene adenosine; toyocamycin; 1-methyladenosine; N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptopurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate; 5'-adenosine triphosphate; phenylisopropyl-adenosine; 1-Methylisoguanosine; N6-cyclohexyladenosine; N6-cyclopentyladenosine; 2-chloro-N6-cyclopentyladenosine; 2-chloroadenosine; adenosine amine congener; 2-p-(2-carboxy-ethyl) phenethyl-amino-5'-N-ethylcarboxamido-adenosine; N-ethylcarboxamido-adenosine; napthyl-substituted aralkoxyadenosine; 5'(N-cyclopropyl)-carboxamidoadenosine; 2-chloroadenosine; N6-phenyladenosine; N6-phenylethyladenosine; and 2-phenylaminoadenosine.

66. (New) The method of claim 54, wherein the adenosine analog is 5'-adenosine monophosphate; 5'-adenosine diphosphate; or 5'-adenosine triphosphate.

67. (New) A method for enhancing the condition of unbroken skin of a mammal by reducing one or more of wrinkling, roughness, dryness, or laxity of the skin, the method comprising topically applying to the skin a composition comprising an adenosine analog in an amount effective to enhance the condition of the skin, wherein the adenosine analog concentration is about 10^{-4} M to 10^{-7} M.

68. (New) The method of claim 67, wherein the adenosine analog concentration is about 10^{-4} M.

69. (New) The method of claim 67, wherein the adenosine analog is selected from the group consisting of 2'-deoxyadenosine; 2',3'-isopropoylidene adenosine; toyocamycin; 1-methyladenosine; N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptopurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate; 5'-adenosine triphosphate; phenylisopropyl-adenosine; 1-Methylisoguanosine; N6-cyclohexyladenosine; N6-cyclopentyladenosine; 2-chloro-N6-cyclopentyladenosine; 2-chloroadenosine; adenosine amine congener; 2-p-(2-carboxy-ethyl) phenethyl-amino-5'-N-ethylcarboxamido-adenosine; N-ethylcarboxamido-adenosine; napthyl-substituted aralkoxyadenosine; 5'(N-cyclopropyl)-carboxamidoadenosine; 2-chloroadenosine; N6-phenyladenosine; N6-phenylethyladenosine; and 2-phenylaminoadenosine.

70. (New) The method of claim 67, wherein the adenosine analog is 5'-adenosine monophosphate; 5'-adenosine diphosphate; or 5'-adenosine triphosphate.

71. (New) A composition comprising adenosine or an adenosine analog in a concentration of about 10^{-4} M to 10^{-7} M, and an angiogenesis factor.

72. (New) The composition of claim 71, wherein the angiogenesis factor is vascular endothelial growth factor or basic fibroblast growth factor.

73. (New) The composition of claim 71, further comprising a conditioning agent.